Xenetic Biosciences (FRA:3XB0) 3-Year Book Growth Rate : -23.10% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Xenetic Biosciences 3-Year Book Growth Rate?

Xenetic Biosciences's Book Value per Share for the quarter that ended in Mar. 2024 was €5.21.

During the past 12 months, Xenetic Biosciences's average Book Value per Share Growth Rate was -33.60% per year. During the past 3 years, the average Book Value per Share Growth Rate was -23.10% per year. During the past 5 years, the average Book Value per Share Growth Rate was -40.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Xenetic Biosciences was -9.90% per year. The lowest was -58.60% per year. And the median was -31.80% per year.

Competitive Comparison of Xenetic Biosciences's 3-Year Book Growth Rate

For the Biotechnology subindustry, Xenetic Biosciences's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xenetic Biosciences's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Xenetic Biosciences's 3-Year Book Growth Rate falls into.

Xenetic Biosciences 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Xenetic Biosciences (FRA:3XB0) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Xenetic Biosciences 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Xenetic Biosciences's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Xenetic Biosciences (FRA:3XB0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenetic Biosciences Inc (FRA:3XB0) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

XBIO:USA

Address

945 Concord Street, Framingham, MA, USA, 01701

Website

https://www.xeneticbio.com

Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

Xenetic Biosciences (FRA:3XB0) Headlines

No Headlines